Literature DB >> 6407670

Treatment of angina pectoris with nifedipine.

J R Idle, P S Sever.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6407670      PMCID： PMC1548302          DOI： 10.1136/bmj.286.6382.1978-e

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  Genetically determined oxidation capacity and the disposition of debrisoquine.

Authors:  T P Sloan; R Lancaster; R R Shah; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

2.  Identification of nifedipine metabolites and their determination by gas chromatography.

Authors:  S Kondo; A Kuchiki; K Yamamoto; K Akimoto; K Takahashi; N Awata; I Sugimoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1980-01       Impact factor: 1.645

Review 3.  Clinical pharmacokinetics of calcium channel antagonists.

Authors:  R G McAllister
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

4.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith; J D Lockhart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30

5.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321
  5 in total
  4 in total

1.  Twelve hour (trough) plasma nifedipine concentrations during chronic treatment with nifedipine retard.

Authors:  M Beerahee; M R Wilkins; D B Jack; D G Beevers; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Variability of plasma drug concentrations: some observations.

Authors:  D B Jack; M R Wilkins; M J Kendall; P E Hall
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Protecting the poor metaboliser--from what?

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

4.  Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.

Authors:  D W Clark; I R Edwards
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.